Metadate CD

Last updated on RxList: 4/21/2021
Metadate CD Side Effects Center

What Is Metadate CD?

Metadate CD (methylphenidate hydrochloride) Extended-Release Capsules is a central nervous system (CNS) stimulant used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.

What Are Side Effects of Metadate CD?

Common side effects of Metadate CD include:

  • headache,
  • stomach pain,
  • loss of appetite,
  • weight loss,
  • trouble sleeping (insomnia),
  • dizziness,
  • nausea,
  • vomiting,
  • lightheadedness,
  • irritability,
  • nervousness,
  • blurred vision or other vision problems,
  • dry mouth,
  • constipation,
  • sweating,
  • skin rash,
  • numbness/tingling/cold feeling in your hands or feet,
  • blue fingers or toes, or
  • (rarely) drowsiness.
  • Metadate CD may raise your blood pressure. Check your blood pressure regularly and tell your doctor if the results are high.

Dosage for Metadate CD

The recommended starting dose of Metadate CD is 20 mg once daily. Dosage may be adjusted in weekly 10-20 mg increments to a maximum of 60 mg/day, depending upon tolerability and effectiveness.

What Drugs, Substances, or Supplements Interact with Metadate CD?

Metadate CD may interact with blood thinners, clonidine, dobutamine, epinephrine, isoproterenol, cold/allergy medicine that contains phenylephrine potassium citrate, sodium acetate, sodium bicarbonate, citric acid, potassium citrate, sodium citrate and citric acid, medications to treat high or low blood pressure, stimulant medications or diet pills, seizure medicine, or antidepressants. Tell your doctor all medications you are taking.

Metadate CD During Pregnancy or Breastfeeding

Metadate CD should be used only when prescribed during pregnancy. It is not known whether this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Metadate CD (methylphenidate hydrochloride) Extended-Release Capsules Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

ADHD Symptoms in Children See Slideshow
Metadate CD Consumer Information

3 pharmacies near 20147 have coupons for Adhansia XR (Brand Names:Metadate CD for 20MG)

CVS Pharmacy
CVS Pharmacy
$10

Est. Regular Price

$315.1

with free coupon

View Coupon
Costco
Costco
$10

Est. Regular Price

$316.96

with free coupon

View Coupon
Walgreens
Walgreens
$10

Est. Regular Price

$317.77

with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • signs of heart problems--chest pain, trouble breathing, feeling like you might pass out;
  • signs of psychosis--hallucinations (seeing or hearing things that are not real), new behavior problems, aggression, hostility, paranoia;
  • signs of circulation problems--numbness, pain, cold feeling, unexplained wounds, or skin color changes (pale, red, or blue appearance) in your fingers or toes; or
  • penis erection that is painful or lasts 4 hours or longer.

Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.

Methylphenidate can affect growth in children. Your child's height and weight may need to be checked often. Tell your doctor if your child is not growing at a normal rate.

Common side effects may include:

  • sweating, increased blood pressure;
  • mood changes, anxiety, feeling nervous or irritable, trouble sleeping;
  • fast heart rate, pounding heartbeats or fluttering in your chest;
  • loss of appetite, weight loss;
  • dry mouth, nausea, vomiting, stomach pain, indigestion; or
  • headache, dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Metadate CD (Methylphenidate Hydrochloride Extended-Release Capsules)

QUESTION

The abbreviated term ADHD denotes the condition commonly known as: See Answer
Metadate CD Professional Information

SIDE EFFECTS

The premarketing development program for METADATE CD included exposures in a total of 228 participants in clinical trials (188 pediatric patients with ADHD, 40 healthy adult subjects). These participants received METADATE CD 20, 40, and/or 60 mg/day. The 188 patients (ages 6 to 15) were evaluated in one controlled clinical study, one controlled, crossover clinical study, and one uncontrolled clinical study. Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs.

Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse events.

The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

Adverse Findings In Clinical Trials With METADATE CD

Adverse Events Associated With Discontinuation Of Treatment

In the 3-week placebo-controlled, parallel-group trial, two METADATE CD-treated patients (1%) and no placebo-treated patients discontinued due to an adverse event (rash and pruritus; and headache, abdominal pain, and dizziness, respectively).

Adverse Events Occurring At An Incidence Of 5% Or More Among METADATE CD-Treated Patients

Table 1 enumerates, for a pool of the three studies in pediatric patients with ADHD, at METADATE CD doses of 20, 40, or 60 mg/day, the incidence of treatment-emergent adverse events. One study was a 3-week placebo-controlled, parallel-group trial, one study was a controlled, crossover trial, and the third study was an open titration trial. The table includes only those events that occurred in 5% or more of patients treated with METADATE CD where the incidence in patients treated with METADATE CD was greater than the incidence in placebo-treated patients.

The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.

TABLE 1 : Incidence of Treatment-Emergent Events1 in a Pool of 3-4 Week Clinical Trials of METADATE CD

Body System Preferred Term METADATE CD
(n=188)
Placebo
(n=190)
General Headache 12% 8%
Abdominal pain (stomach ache) 7% 4%
Digestive System Anorexia (loss of appetite) 9% 2%
Nervous System Insomnia 5% 2%
1Events, regardless of causality, for which the incidence for patients treated with METADATE CD was at least 5% and greater than the incidence among placebo-treated patients. Incidence has been rounded to the nearest whole number.

Adverse Events With Other Marketed Methylphenidate HCl Products

Nervousness and insomnia are the most common adverse reactions reported with other methylphenidate products. Other reactions include hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, both up and down; tachycardia; angina; cardiac arrhythmia; abdominal pain; weight loss during prolonged therapy. There have been rare reports of Tourette's Syndrome and obsessive-compulsive disorder. Toxic psychosis has been reported. Although a definite causal relationship has not been established, the following have been reported in patients taking this drug: instances of abnormal liver function, ranging from transaminase elevation to hepatic coma; isolated cases of cerebral arteritis and/or occlusion; leucopenia and/or anemia; transient depressed mood; a few instances of scalp hair loss. Very rare reports of neuroleptic malignant syndrome (NMS) have been reported, and, in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten year old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.

In children, loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia and tachycardia may occur more frequently; however, any of the other adverse reactions listed above may also occur.

Postmarketing Experience

In addition to the adverse events listed above, the following have been reported in patients receiving METADATE CD worldwide. The list is alphabetized: abnormal behavior, aggression, anxiety, bruxism, cardiac arrest, depression, fixed drug eruption, hyperactivity, irritability, migraine, obsessive-compulsive disorder, peripheral coldness, Raynaud's phenomenon, reversible ischaemic neurological deficit, sudden death, suicidal behavior (including completed suicide), and thrombocytopenia. Data are insufficient to support an estimation of incidence or establish causation.

Drug Abuse And Dependence

Controlled Substance Class

METADATE CD, like other methylphenidate products, is classified as a Schedule II controlled substance by federal regulation.

Abuse, Dependence, And Tolerance

See WARNINGS for boxed warning containing drug abuse and dependence information.

Read the entire FDA prescribing information for Metadate CD (Methylphenidate Hydrochloride Extended-Release Capsules)

© Metadate CD Patient Information is supplied by Cerner Multum, Inc. and Metadate CD Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors